Learn about GIST tumor, also known as gastrointestinal stromal tumor, diagnosis, including relevant healthcare, clinical documentation, and medical coding information. Find details on GIST treatment, prognosis, and pathology. This resource provides valuable information for medical professionals, patients, and caregivers seeking knowledge about GIST tumors.
Also known as
Malignant neoplasm of small intestine
Cancers specifically affecting the small intestine, including GISTs.
Malignant neoplasm of colon
Cancers affecting the colon, where GISTs can sometimes occur.
Secondary malignant neoplasm of digestive system
Metastatic cancer spread to the digestive system, sometimes from a primary GIST.
Neoplasm of uncertain behavior of digestive organs
Classifies GISTs that haven't been definitively determined as benign or malignant.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the GIST malignant?
When to use each related code
| Description |
|---|
| Tumor of the GI tract connective tissue. |
| Smooth muscle tumor of the GI tract. |
| Tumor of the GI tract neuroendocrine cells. |
Missing or unspecified primary site of the GIST tumor impacts accurate coding and staging, affecting reimbursement and treatment planning.
Documentation of mitotic rate is crucial for risk stratification and proper code assignment, influencing prognosis and treatment.
Accurate tumor size is essential for appropriate code selection and staging, impacting treatment strategy and patient outcomes.
Q: What are the most effective current treatment strategies for metastatic GIST, including advanced imatinib-resistant cases?
A: The treatment of metastatic or advanced imatinib-resistant GIST is complex and requires a multidisciplinary approach. First-line treatment for metastatic GIST typically involves imatinib mesylate, a tyrosine kinase inhibitor. However, resistance can develop. For imatinib-resistant cases, second-line options include sunitinib, and if sunitinib fails, regorafenib is a third-line option. Further, ripretinib is approved for fourth-line treatment of advanced GIST with a prior history of 3 or more kinase inhibitor therapies. Clinical trials evaluating new targeted therapies and combination strategies are also crucial for exploring potential advancements in GIST treatment. Explore how multidisciplinary tumor boards can contribute to personalized treatment decisions for complex GIST cases.
Q: How can I differentiate between a GIST (Gastrointestinal Stromal Tumor) and other mesenchymal tumors of the GI tract based on immunohistochemical staining and molecular profiling?
A: Differentiating GIST from other mesenchymal tumors relies heavily on immunohistochemistry (IHC) and molecular profiling. GISTs characteristically express CD117 (KIT) in almost all cases. CD34 is positive in most cases, but its absence doesn't rule out GIST. DOG1 is another helpful marker, especially in KIT-negative GISTs. Further, mutational analysis targeting KIT and PDGFRA plays a key role in diagnosis and predicting response to targeted therapy. Consider implementing routine molecular testing for KIT/PDGFRA mutations for all suspected GIST cases to accurately guide treatment selection. The distinct IHC profile of GIST, particularly CD117 positivity, coupled with specific genetic findings allows for effective differentiation from other mesenchymal tumors like leiomyomas, leiomyosarcomas, and schwannomas. Learn more about the role of molecular diagnostics in personalizing GIST management.
Patient presents with symptoms suggestive of a gastrointestinal stromal tumor (GIST). These symptoms include [Insert specific patient symptoms e.g., abdominal pain, nausea, vomiting, early satiety, palpable mass, gastrointestinal bleeding melena, hematochezia]. Physical examination revealed [Insert relevant physical exam findings e.g., abdominal tenderness, palpable mass]. Differential diagnosis includes leiomyoma, leiomyosarcoma, schwannoma, and other mesenchymal tumors. Imaging studies, including [Specify imaging modality e.g., CT scan of the abdomen and pelvis, MRI, endoscopic ultrasound], were ordered to evaluate the suspected GIST and assess tumor size, location (gastric GIST, small intestine GIST, colon GIST, rectal GIST, esophageal GIST), and potential metastasis. Biopsy is planned for histopathological confirmation of GIST diagnosis and assessment of mitotic index, which is crucial for risk stratification and prognostication. Based on clinical and radiographic findings, the preliminary diagnosis is consistent with a GIST. Further evaluation, including mutation testing for KIT (CD117) and PDGFRA, will be conducted to inform treatment decisions. Treatment options for GIST, including surgical resection (complete resection, partial resection, laparoscopic surgery), targeted therapy with imatinib mesylate or other tyrosine kinase inhibitors (TKIs), and clinical trials, will be discussed with the patient following complete diagnostic workup. Patient education regarding GIST prognosis, recurrence risk, and surveillance strategies will be provided. ICD-10 code C49.4 (malignant neoplasm of the small intestine, other and unspecified parts) or other appropriate code based on location will be applied. Appropriate CPT codes for procedures performed will also be documented.